Quantcast
Last updated on April 18, 2014 at 16:16 EDT

Latest Atheroma Stories

2014-03-17 16:28:30

"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets" TSX Exchange Symbol: RVX CALGARY, March 17, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today that it has received confirmation that its European patent application covering RVX-208 has been granted. European Patent no. 2118074 is titled "Compounds for the prevention and treatment of...

2014-03-04 16:12:53

Noninvasive imaging of carotid artery plaque with MRI can accurately predict future cardiovascular events like strokes and heart attacks in people without a history of cardiovascular disease, according to a new study published online in the journal Radiology. Researchers have long known that some arterial plaque is more dangerous because of its vulnerability to rupture. MRI can discern features of vulnerable plaque, such as a lipid core with a thin fibrous cap. This ability makes MRI a...

2014-03-03 23:00:09

Noninvasive imaging of carotid artery plaque with MRI can accurately predict future cardiovascular events like strokes and heart attacks in people without a history of cardiovascular disease, according to a new study published online, March 4, in the journal Radiology. Oak Brook, Ill. (PRWEB) March 03, 2014 Noninvasive imaging of carotid artery plaque with MRI can accurately predict future cardiovascular events like strokes and heart attacks in people without a history of cardiovascular...

2014-02-28 23:26:13

Icahn School of Medicine at Mount Sinai study suggests early-stage atherosclerosis is reversible, and identifies new genetic targets for fighting advanced atherosclerosis New York, NY (PRWEB) February 28, 2014 Research at Icahn School of Medicine at Mount Sinai has led to important new discoveries about the process behind regression of atherosclerosis, the main underlying cause of heart attack and stroke. In the paper published today in PLoS Genetics, scientists from Mount Sinai and the...

2014-01-12 23:00:32

Mount Sinai Heart leads international research team testing new sugar-based tracer to help in the cardiovascular imaging hunt for inflamed high-risk, vulnerable artery plaques before they rupture. New York, NY (PRWEB) January 12, 2014 An international research team led by Mount Sinai Heart at Icahn School of Medicine at Mount Sinai is testing its novel sugar-based tracer contrast agent to be used with positron emission tomography (PET) imaging to help in the hunt for dangerous...

2014-01-02 16:22:10

TSX Exchange Symbol: RVX CALGARY, Jan. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that a publication titled "RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist" was published on December 31(st) 2013 in the international, peer-reviewed, open-access online publication PLOS ONE Journal. The publication was authored by Resverlogix staff in combination with collaborators from Xtal Biostructures Inc. in Maryland USA. This publication...

2013-12-05 08:28:48

IRVINE, Calif., Dec. 5, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of...

2013-11-04 08:26:45

"RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma in High Risk CVD Patients" TSX Exchange Symbol: RVX CALGARY, Nov. 4, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced two additional results from the ongoing analysis of its Phase 2b ASSURE clinical trial using intravascular ultrasound (IVUS) to study high-risk cardiovascular disease (CVD) patients for assessing benefits of RVX-208. This lead molecule is a member of a new class of compounds...

2013-10-15 11:59:29

Researchers from the CNIC and the CSIC publish their findings in EMBO Molecular Medicine Researchers of the Spanish research council (Consejo Superior de Investigaciones CientĂ­ficas, CSIC) and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that inhibiting the protein Rcan1 in mice reduces the burden of atherosclerosis, one of the commonest cardiovascular diseases. The results of their study, published in the prestigious journal EMBO Molecular Medicine,...

2013-08-29 08:25:31

TSX Exchange Symbol: RVX CALGARY, Aug. 29, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced they will be hosting a corporate update conference call and webcast with Q&A on September 3(rd) at 11 am MDT. Details for the conference call and webcast are as follows: Link to webcast: http://services.choruscall.ca/links/resverlogix130905.html Dial in numbers: Canada & USA Toll Free Dial In: 1-800-319-4610 Outside of Canada & USA call: +1-604-638-5340...